How they work: two mechanisms, one goal
Growth hormone (GH) secretion from the pituitary is regulated by two opposing signals: GHRH (growth hormone-releasing hormone), which stimulates release, and somatostatin, which inhibits it. Natural GH secretion occurs in pulsatile bursts, primarily during deep sleep and after exercise.
CJC-1295 and ipamorelin amplify this natural pulsatility through two distinct mechanisms:
CJC-1295 (modified GRF 1-29)
CJC-1295 is a synthetic analog of GHRH — the 29-amino-acid active fragment of the natural 44-amino-acid hormone. The "DAC" (Drug Affinity Complex) version binds to albumin, extending its half-life to 6-8 days. The "no DAC" version (also called modified GRF 1-29 or mod-GRF) has a shorter half-life (approximately 30 minutes) but produces more physiological pulsatile release[1].
CJC-1295 acts on the GHRH receptor on pituitary somatotrophs, directly stimulating GH synthesis and release. It amplifies the amplitude of GH pulses without disrupting the natural pulsatile pattern[1].
Ipamorelin
Ipamorelin is a pentapeptide that acts as a selective agonist of the ghrelin receptor (GHS-R1a) — the same receptor that ghrelin, the "hunger hormone," activates. But unlike ghrelin and other GH secretagogues (GHRP-2, GHRP-6, hexarelin), ipamorelin is highly selective: it stimulates GH release with minimal effect on cortisol, prolactin, and aldosterone[2].
This selectivity is ipamorelin's key advantage. GHRP-6, for example, significantly raises cortisol and prolactin in addition to GH. Hexarelin can desensitize the GHS receptor with repeated use. Ipamorelin avoids both of these problems at therapeutic doses[2].
The synergy
GHRH receptor agonism (CJC-1295) and ghrelin receptor agonism (ipamorelin) are synergistic — they amplify GH release more than either alone. The GHRH pathway sets the "amplitude" of the pulse, while the ghrelin pathway sets the "frequency." Together, they produce a robust GH pulse that mimics (and amplifies) the body's natural secretion pattern[3].
The blood work panel: what to monitor
IGF-1 (insulin-like growth factor 1)
IGF-1 is the primary downstream effector of GH. GH stimulates the liver to produce IGF-1, which mediates most of GH's anabolic effects (muscle protein synthesis, bone growth, tissue repair). IGF-1 has a much longer half-life than GH (18-20 hours vs minutes), making it the practical marker for monitoring GH stimulation therapy[4].
| IGF-1 level | Interpretation on peptide therapy | Action |
|---|---|---|
| < 150 ng/mL | Subtherapeutic response | Consider dose increase, verify injection technique |
| 150-250 ng/mL | Therapeutic range for most adults | Maintain current dose |
| 250-300 ng/mL | Upper therapeutic range | Monitor closely; acceptable for some protocols |
| > 300 ng/mL | Supraphysiological | Reduce dose; long-term risks increase |
Important: IGF-1 reference ranges are age-dependent. A 25-year-old naturally has higher IGF-1 than a 55-year-old. The target should be the upper-normal range for your specific age, not an absolute number[4].
Fasting glucose and insulin
Growth hormone is a counter-regulatory hormone to insulin. It promotes lipolysis (fat breakdown) and hepatic glucose output, which can reduce insulin sensitivity. Exogenous GH is well-documented to raise fasting glucose and induce insulin resistance, sometimes to the point of diabetes[5].
Ipamorelin + CJC-1295 produce more physiological GH pulses than continuous exogenous GH, so the glucose impact is generally milder. But it is not zero. Monitor:
- Fasting glucose: Should remain below 100 mg/dL. A rise of 5-10 mg/dL from baseline is common but should be tracked.
- Fasting insulin and HOMA-IR: More sensitive than glucose alone. If HOMA-IR rises above 2.5-3.0, insulin resistance is developing and dose adjustment should be considered.
- HbA1c: Every 3-6 months. Provides the long view on glucose regulation.
Cortisol
Morning cortisol (AM, drawn at 8-10 AM) should remain stable on ipamorelin. Unlike GHRP-2 and GHRP-6, ipamorelin does not significantly stimulate ACTH or cortisol release at therapeutic doses[2]. If cortisol rises significantly from baseline, it may indicate the dose is too high or there is a confounding stressor. Elevated cortisol antagonizes many of the benefits people seek from GH peptides (body composition, sleep, recovery).
Prolactin
Like cortisol, prolactin should remain stable on ipamorelin. GHRP-6 and hexarelin can raise prolactin; ipamorelin generally does not[2]. Elevated prolactin can cause symptoms including decreased libido, mood changes, and in severe cases, galactorrhea. Monitor at baseline and periodically, particularly if symptoms suggest elevation.
Thyroid function (TSH, free T4, free T3)
GH increases the peripheral conversion of T4 to T3 by upregulating type 1 deiodinase activity. This can manifest as slightly increased free T3 and slightly decreased free T4, with TSH remaining stable or mildly increasing if the pituitary senses reduced T4[6].
In people with subclinical or compensated hypothyroidism, GH stimulation can unmask the thyroid insufficiency — the increased T4-to-T3 conversion depletes T4 reserves and TSH rises. If you are on thyroid replacement (levothyroxine), your dose may need upward adjustment after starting GH peptide therapy[6].
Liver enzymes (ALT, AST, GGT)
GH stimulates hepatic protein synthesis and liver metabolism. Mild transient elevations in liver enzymes (ALT, AST) can occur during GH therapy, usually within the first few weeks, and typically resolve. Persistent elevation warrants investigation, as it may indicate fatty liver progression or other hepatic effects[5].
The monitoring timeline
| Timepoint | What to test | Why |
|---|---|---|
| Baseline (before starting) | IGF-1, fasting glucose, fasting insulin, HbA1c, CMP (liver enzymes), TSH, fT4, fT3, AM cortisol, prolactin, CBC, lipid panel | Establishes all reference values |
| 4-6 weeks | IGF-1, fasting glucose, fasting insulin, liver enzymes | Confirms IGF-1 response; catches early glucose or liver effects |
| 3 months | Full panel repeat | Comprehensive check including thyroid, cortisol, prolactin |
| Every 3-6 months ongoing | IGF-1, glucose, insulin, HbA1c, liver enzymes, thyroid | Ongoing safety and efficacy monitoring |
Safety considerations and long-term unknowns
Ipamorelin and CJC-1295 have a reasonable short-term safety profile based on available clinical data. However, several important caveats exist:
- Long-term data is limited: Most clinical studies of these peptides are short-term (weeks to months). Multi-year safety data in healthy adults using them for anti-aging or body composition purposes does not exist[1].
- IGF-1 and cancer risk: Epidemiological studies consistently show an association between higher circulating IGF-1 and increased risk of certain cancers, particularly prostate, breast, and colorectal[7]. This does not prove causation, and the risk-benefit calculus for moderate IGF-1 elevation (staying within age-appropriate reference ranges) is debated. Keeping IGF-1 in the upper-normal rather than supraphysiological range is the conservative approach.
- Contraindications: Active malignancy is an absolute contraindication for GH or GH secretagogue therapy. History of cancer, proliferative diabetic retinopathy, and active intracranial lesions are relative contraindications[4].
- Compound quality: Many peptides are sourced from compounding pharmacies or research chemical suppliers. Purity, sterility, and actual peptide content vary. Using a reputable compounding pharmacy that provides certificates of analysis (COA) with third-party testing is essential[8].
Dosing context
Typical clinical protocols (for reference, not prescriptive):
- Ipamorelin: 100-300 mcg per injection, subcutaneous, 1-3 times daily (often pre-bed and/or pre-exercise)[2]
- CJC-1295 no DAC (mod-GRF 1-29): 100-300 mcg per injection, combined with ipamorelin in the same syringe
- CJC-1295 with DAC: 1-2 mg per injection, 1-2 times per week (due to extended half-life)
- Cycling: Many protocols include 5 days on / 2 days off or 8-12 week cycles with 4-6 week breaks to prevent receptor desensitization, though the evidence for this is largely empirical[3]
Timing: GH release is inhibited by elevated blood sugar and insulin. For maximum effect, inject during a fasted state — at least 2 hours after eating. Pre-bed injection aligns with the natural nocturnal GH surge[3].
What the research actually shows vs what is claimed
It is important to separate what is supported by published evidence from what is extrapolated from GH biology or reported anecdotally:
- Supported: Ipamorelin and CJC-1295 reliably increase GH secretion and IGF-1 levels[1][2]. Ipamorelin is selective (minimal cortisol/prolactin impact)[2]. GH improves body composition (reduced fat mass, increased lean mass)[5].
- Probable but less rigorous: Improved sleep quality, faster recovery from exercise, improved skin elasticity. These are consistent with GH biology but not rigorously studied specifically with ipamorelin + CJC-1295 in healthy adults.
- Overstated: Claims of dramatic muscle growth, fat loss, or "anti-aging" at physiological GH levels. The body composition effects are real but modest in most studies — far less than what exogenous GH at supraphysiological doses produces, and far less than what social media suggests[5].